Your browser doesn't support javascript.
loading
Long noncoding RNA Smyca coactivates TGF-ß/Smad and Myc pathways to drive tumor progression.
Chen, Hsin-Yi; Chan, Shu-Jou; Liu, Xinxin; Wei, An-Chi; Jian, Ru-In; Huang, Kuan-Wei; Lang, Yaw-Dong; Shih, Jou-Ho; Liao, Chun-Chieh; Luan, Chiu-Lin; Kao, Yu-Tung; Chiang, Shang-Yin; Hsiao, Pei-Wen; Jou, Yuh-Shan; Chen, Yunching; Chen, Ruey-Hwa.
Afiliación
  • Chen HY; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110, Taiwan.
  • Chan SJ; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110, Taiwan.
  • Liu X; Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
  • Wei AC; Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.
  • Jian RI; Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
  • Huang KW; Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.
  • Lang YD; Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
  • Shih JH; Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.
  • Liao CC; Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
  • Luan CL; Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.
  • Kao YT; Institute of Biomedical Engineering and Frontier Research Center On Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu, 300, Taiwan.
  • Chiang SY; Institute of Biomedical Sciences, Academia Sinica, Taipei, 115, Taiwan.
  • Hsiao PW; Cancer Progression Research Center, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
  • Jou YS; Institute of Biomedical Sciences, Academia Sinica, Taipei, 115, Taiwan.
  • Chen Y; Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
  • Chen RH; Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, 106, Taiwan.
J Hematol Oncol ; 15(1): 85, 2022 07 06.
Article en En | MEDLINE | ID: mdl-35794621
BACKGROUND: Metastasis and chemoresistance are major culprits of cancer mortality, but factors contributing to these processes are incompletely understood. METHODS: Bioinformatics methods were used to identify the relations of Smyca expression to clinicopathological features of human cancers. RNA-sequencing analysis was used to reveal Smyca-regulated transcriptome. RNA pull-down and RNA immunoprecipitation were used to examine the binding of Smyca to Smad3/4 and c-Myc/Max. Chromatin immunoprecipitation and chromatin isolation by RNA purification were used to determine the binding of transcription factors and Smyca to various gene loci, respectively. Real-time RT-PCR and luciferase assay were used to examine gene expression levels and promoter activities, respectively. Xenograft mouse models were performed to evaluate the effects of Smyca on metastasis and chemoresistance. Nanoparticle-assisted gapmer antisense oligonucleotides delivery was used to target Smyca in vivo. RESULTS: We identify lncRNA Smyca for its association with poor prognosis of many cancer types. Smyca potentiates metabolic reprogramming, migration, invasion, cancer stemness, metastasis and chemoresistance. Mechanistically, Smyca enhances TGF-ß/Smad signaling by acting as a scaffold for promoting Smad3/Smad4 association and further serves as a Smad target to amplify/prolong TGF-ß signaling. Additionally, Smyca potentiates c-Myc-mediated transcription by enhancing the recruitment of c-Myc/Max complex to a set of target promoters and c-Myc binding to TRRAP. Through potentiating TGF-ß and c-Myc pathways, Smyca synergizes the Warburg effect elicited by both pathways but evades the anti-proliferative effect of TGF-ß. Targeting Smyca prevents metastasis and overcomes chemoresistance. CONCLUSIONS: This study uncovers a lncRNA that coordinates tumor-relevant pathways to orchestra a pro-tumor program and establishes the clinical values of Smyca in cancer prognosis and therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ARN Largo no Codificante / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ARN Largo no Codificante / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido